Wilms tumor (nephroblastoma), version 2.2021 Guidelines


Authors: Balis, F.; Green, D. M.; Anderson, C.; Cook, S.; Dhillon, J.; Gow, K.; Hiniker, S.; Jasty-Rao, R.; Lin, C.; Lovvorn, H. 3rd; MacEwan, I.; Martinez-Agosto, J.; Mullen, E.; Murphy, E. S.; Ranalli, M.; Rhee, D.; Rokitka, D.; Tracy, E. L.; Vern-Gross, T.; Walsh, M. F.; Walz, A.; Wickiser, J.; Zapala, M.; Berardi, R. A.; Hughes, M.
Title: Wilms tumor (nephroblastoma), version 2.2021
Abstract: The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT. © National Comprehensive Cancer Network, Inc. 2021.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 19
Issue: 8
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2021-08-01
Start Page: 945
End Page: 977
Language: English
DOI: 10.6004/jnccn.2021.0037
PROVIDER: scopus
PUBMED: 34416707
DOI/URL:
Notes: Review -- Export Date: 1 September 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Francis Walsh
    156 Walsh
Related MSK Work